FOUNDATIONONE®CDx

PATIENT
Chang, Chin-Wei

TUMOR TYPE
Colon adenocarcinoma (CRC)
COUNTRY CODE
TW

REPORT DATE
10 Mar 2022
ORDERED TEST #
ORD-1314037-01

ABOUT THE TEST FoundationOne®CDx is a next-generation sequencing (NGS) based assay that identifies genomic findings within hundreds of cancer-related genes.

PATIENT
DISEASE Colon adenocarcinoma (CRC)
NAME Chang, Chin-Wei
DATE OF BIRTH 18 May 1959
SEX Male
MEDICAL RECORD # 44137044

PHYSICIAN
ORDERING PHYSICIAN Yeh, Yi-Chen
MEDICAL FACILITY Taipei Veterans General Hospital
ADDITIONAL RECIPIENT None
MEDICAL FACILITY ID 205872
PATHOLOGIST Not Provided

SPECIMEN
SPECIMEN SITE Chest Wall
SPECIMEN ID S111-01929C
SPECIMEN TYPE Slide Deck
DATE OF COLLECTION 13 January 2022
SPECIMEN RECEIVED 04 March 2022

Biomarker Findings

Microsatellite status - MS-Stable
Tumor Mutational Burden - 5 Muts/Mb

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

KRAS G12D
NRAS wildtype
APC T1556fs*3
PIK3CA E545K
CDKN2A/B CDKN2B loss, CDKN2A loss
SMAD4 E538*
SOX9 Q411*

2 Disease relevant genes with no reportable alterations: *BRAF, NRAS*

† See About the Test in appendix for details.

Report Highlights

- Targeted therapies with **potential resistance** based on this patient's genomic findings: ⊗ **Cetuximab** (p. 9), **Panitumumab** (p. 9)
- Evidence-matched **clinical trial options** based on this patient's genomic findings: (p. 10)

BIOMARKER FINDINGS	THERAPY AND CLINICAL TRIAL IMPLICATIONS	
Microsatellite status - MS-Stable	**No therapies or clinical trials.** see Biomarker Findings section	
Tumor Mutational Burden - 5 Muts/Mb	**No therapies or clinical trials.** see Biomarker Findings section	
GENOMIC FINDINGS	**THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)**	**THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)**
***KRAS* -** G12D		
10 Trials see p. 11	*Cetuximab* ⊗ *Panitumumab* ⊗	none
***NRAS* -** wildtype		
0 Trials	*Cetuximab* ⊗ *Panitumumab* ⊗	none
***APC* -** T1556fs*3		
4 Trials see p. 10	none	none
***PIK3CA* -** E545K		
10 Trials see p. 13	none	none

⊗ *Extensive evidence showing variant(s) in this sample may confer resistance to this therapy*

Electronically signed by Erik Williams, M.D. | 10 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and exhaustive. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies.

Therapies contained in this report may have been approved by the US FDA.

Electronically signed by Erik Williams, M.D. | 10 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

BIOMARKER

Microsatellite status

RESULT
MS-Stable

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence, MSS tumors are significantly less likely than MSI-H tumors to respond to anti-PD-1 immune checkpoint inhibitors[1-3], including approved therapies nivolumab and pembrolizumab[4]. In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI-H and experienced a significantly higher ORR compared with non-MSI-H cases (70% vs. 12%, p=0.001)[5]. For patients with chemotherapy-refractory microsatellite-stable (MSS) metastatic colorectal cancer (CRC), a Phase 3 trial reported no OS advantage from the combination of the PD-L1 inhibitor atezolizumab plus cobimetinib relative to regorafenib (8.9 vs. 8.5 months, HR=1.00); atezolizumab monotherapy similarly did not prolong OS (7.1 vs. 8.5 months, HR=1.19)[6]. For patients with MSS CRC, a Phase 2 study combining ipilimumab and nivolumab reported an overall DCR of 25% (10/40)[7]. Two Phase 1 studies for patients with MSS CRC treated with regorafenib and nivolumab reported PFSs of 7.9 months[8] and 5.7 months[9], and a patient with MSS CRC refractory to chemotherapy treated with the PD-1 inhibitor sintilimab and regorafenib reported a CR[10].

— Nontargeted Approaches —

MSI has not been found to be a predictive biomarker for combination chemotherapy regimens, including FOLFOX[11-12] and FOLFIRI[13-14]. Patients with MSS CRC are more likely to benefit from postsurgical fluorouracil (FU)-based adjuvant therapy[15-16] but less likely to benefit from irinotecan chemotherapy[17].

FREQUENCY & PROGNOSIS

MSS colorectal cancers (CRCs) make up 70-85% of CRC cases[3,18-22]. MSS colorectal cancers are molecularly heterogeneous, driven by diverse mechanisms such as extensive DNA methylation, oncogenic mutations in KRAS or BRAF, or chromosomal instability[22]. Multiple studies have shown that MSS CRCs have a worse prognosis than MSI-high tumors[18,23-29].

FINDING SUMMARY

Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor[20]. Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2[20,30-31]. This sample is microsatellite-stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers[19,32-33]. MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins[19-20,31,33].

Electronically signed by Erik Williams, M.D. | 10 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

BIOMARKER

Tumor Mutational Burden

RESULT
5 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1[34-36], anti-PD-1 therapies[34-37], and combination nivolumab and ipilimumab[38-43]. In multiple pan-tumor studies, higher TMB has been reported to be associated with increased ORR and OS from treatment with immune checkpoint inhibitors[34-37,44]. Higher TMB was found to be significantly associated with improved OS upon immune checkpoint inhibitor treatment for patients with 9 types of advanced tumors[34]. Analyses across several solid tumor types reported that patients with higher TMB (defined as ≥16-20 Muts/Mb) achieved greater clinical benefit from PD-1 or PD-L1-targeting monotherapy, compared with patients with higher TMB treated with chemotherapy[45] or those with lower TMB treated with PD-1 or PD-L1-targeting agents[35]. However, the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors found significant improvement in ORR for patients with TMB ≥10 Muts/Mb (based on this assay or others) compared to those with TMB <10 Muts/Mb, in a large cohort that included multiple tumor types; similar findings were observed in the KEYNOTE 028 and 012 trials[37,44]. Together, these studies suggest that patients with TMB ≥10 Muts/Mb may derive clinical benefit from PD-1 or PD-L1 inhibitors. In CRC specifically, a retrospective analysis of immune checkpoint inhibitor efficacy reported significantly improved OS for patients with tumors harboring TMB ≥9.8 Muts/MB compared with those with tumors with TMB <9.8 Muts/Mb (~ equivalency <12 Muts/Mb as measured by this assay)[34]. Another retrospective study reported that a TMB ≥12 Muts/Mb cutoff identifies >99% of MSI-High CRC cases but only 3% of MSS cases, indicating the utility of this cutoff for identification of patients with CRC likely to benefit from treatment with immune checkpoint inhibitors[46].

FREQUENCY & PROGNOSIS

Elevated tumor mutational burden (TMB) has been reported in 8-25% of colorectal cancer (CRC) samples[21,47-48]. Multiple studies have reported that up to 90% of hypermutated CRC cases exhibit high levels of microsatellite instability (MSI-H) and mismatch repair deficiency (MMR-D)[21,47]. Increased TMB is significantly associated with MSI-H and MMR-D, with studies reporting that 100% of MSI-H CRCs harbor elevated TMB and conversely that 100% of tumors with low TMB harbor intact MMR[47]. A subset of CRCs that harbor increased TMB but not MSI-H are driven by mutations in POLE, which leads to an "ultramutated" phenotype with especially high TMB[21,47]. Tumors with increased TMB harbor BRAF V600E mutations more frequently than those with low TMB[21,47], whereas TMB-low tumors more frequently harbor mutations in TP53 and APC[21]. In a study for 61 patients with metastatic, microsatellite stable (MSS) CRC treated with best standard of care, plasma TMB scores ≥28 muts/Mb (approximately 14 muts/Mb as measured by this assay) were associated with reduced OS as compared with plasma TMB scores <28 muts/Mb (3.0 vs. 5.3 months, HR 0.76, p=0.007), whereas tissue TMB was not found to be prognostic in this population[49].

FINDING SUMMARY

Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma[50-51] and cigarette smoke in lung cancer[52-53], treatment with temozolomide-based chemotherapy in glioma[54-55], mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes[21,56-59], and microsatellite instability (MSI)[21,56,59]. This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents[34,44,46].

Electronically signed by Erik Williams, M.D. | 10 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
KRAS

ALTERATION
G12D

TRANSCRIPT ID
NM_004985

CODING SEQUENCE EFFECT
35G>A

VARIANT ALLELE FREQUENCY (% VAF)
83.4%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Preclinical evidence suggests that KRAS activation may predict sensitivity to MEK inhibitors, such as trametinib, binimetinib, cobimetinib, and selumetinib[60-65]. However, multiple clinical trials have reported lack of efficacy of trametinib and other MEK inhibitors when used as monotherapy for treatment of patients with KRAS-mutant CRC[66-70]. Both clinical[71-72] and preclinical[73-74] studies suggest that combinatorial approaches including MEK inhibitors are likely to be more effective for the treatment of CRC, including strategies such as combination of MEK inhibitors with PI3K inhibitors[72], RAF inhibitors[73], pan-ERBB inhibitors[74], or chemotherapeutic agents[71]. In a Phase 1 study evaluating the MEK-pan-RAF dual inhibitor CH5126766, 6 patients harboring KRAS mutations experienced PRs, including 3 with non-small cell lung cancer (NCSLC), 1 with low-grade serous ovarian carcinoma (LGSOC), 1 with endometrial adenocarcinoma, and 1 with multiple myeloma[75]. Combination of CH5126766 with the FAK inhibitor defactinib elicited PR rates of 50% (4/8) for patients with KRAS-mutated low-grade serous ovarian cancer and 12% (2/17) for patients with KRAS-mutated non-small cell lung cancer (NSCLC) in a Phase 1 study[76-77] . Preclinical and clinical data suggest that KRAS mutations may predict clinical benefit from SHP2 inhibitors[78-79]. A Phase 1 study of RMC-4630 for relapsed/refractory solid tumors reported a DCR of 58% (23/40) for patients with NSCLC and KRAS mutations and a DCR of 75% (12/16) for patients with NSCLC and KRAS G12C mutations[80]. Interim results from a Phase 1/2 study of RMC-4630 plus cobimetinib reported tumor reduction in 3 of 8 patients with KRAS-mutated colorectal cancer[81]. Preclinical data suggest that KRAS mutation may confer sensitivity to SOS1 inhibitors[82-83]. Phase 1 studies of the SOS1 inhibitor BI 1701963 alone or in combination with MEK inhibitors, KRAS G12C inhibitors, or irinotecan are recruiting for patients with solid tumors harboring KRAS mutations[84-85] . Preclinical and limited clinical evidence suggest that KRAS mutation may predict sensitivity to PLK1 inhibitors[86]. A Phase 1b/2 study of PLK1 inhibitor onvansertib in combination with FOLFIRI and bevacizumab for patients with KRAS-mutated metastatic CRC previously treated with chemotherapy reported an 87.5% (7/8; 3 PR, 4 SD) clinical benefit rate, with 1 patient going on to successful curative surgery[87].

— Potential Resistance —

Activating mutations in KRAS or NRAS are associated with lack of clinical benefit from cetuximab[88-91] or panitumumab[92-94] for patients with CRC. Therefore, activating mutations in either gene indicate against the use of cetuximab and panitumumab (NCCN Colon Cancer Guidelines, v3.2021).

FREQUENCY & PROGNOSIS

Mutations in KRAS have been reported in approximately 35-50% of colorectal cancers (CRCs)[95-103]. Numerous studies have reported that KRAS mutations are associated with increased metastasis, adverse clinicopathological features, and shorter survival of patients with CRC[97-100,104-105].

FINDING SUMMARY

KRAS encodes a member of the RAS family of small GTPases. Activating mutations in RAS genes can cause uncontrolled cell proliferation and tumor formation[61,106]. KRAS alterations affecting amino acids G12, G13, Q22, P34, A59, Q61, and A146, as well as mutations G10_A11insG, G10_A11insAG (also reported as G10_A11dup and G12_G13insAG), A18D, L19F, D33E, G60_A66dup/E62_A66dup, E62K, E63K, R68S, and K117N have been characterized as activating and oncogenic[61,107-129].

GENE
NRAS

ALTERATION
wildtype

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Lack of mutations in KRAS or NRAS is associated with clinical benefit of treatment with EGFR-targeting antibodies cetuximab[88-91] or panitumumab[92-94] for patients with CRC. Therefore, these agents are indicated to treat patients with CRC lacking such mutations (NCCN Guidelines v3.2021).

FREQUENCY & PROGNOSIS

The majority of colorectal cancers (CRCs) (91-98%) have been reported to lack NRAS mutations[21,103,130-135]. NRAS wild-type status has been reported to be associated with decreased frequency of metastasis[103] and longer survival[135-136] of patients with CRC.

FINDING SUMMARY

NRAS encodes a member of the RAS family of small GTPases that mediate transduction of growth signals. Activation of RAS signaling causes cell growth, differentiation, and survival by activating the RAF-MAPK-ERK, PI3K, and other pathways[61]. No alterations in NRAS were identified in this case.

Electronically signed by Erik Williams, M.D. | 10 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
APC

ALTERATION
T1556fs*3

TRANSCRIPT ID
NM_000038

CODING SEQUENCE EFFECT
4666_4667insA

VARIANT ALLELE FREQUENCY (% VAF)
72.4%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no approved drugs targeting APC inactivation in cancer. Loss of APC function leads to accumulation of beta-catenin and upregulation of WNT pathway transcription programs[137], and potential therapeutic approaches to target this pathway include CBP/beta-catenin antagonists, which interfere with the ability of beta-catenin to interact with transcriptional co-activator CBP[138-139]. In a Phase 1 trial of the CBP/beta-catenin antagonist E7386, 1 patient with APC-mutated small bowel adenocarcinoma achieved a PR with tumor shrinkage of -69% and response duration of 165 days[140]; preclinical data support sensitivity of APC-deficient gastric or colorectal cancer models to E7386[141-142].

FREQUENCY & PROGNOSIS

APC alterations have been found in 77% of tumors in the Colorectal Adenocarcinoma TCGA dataset[21]. Inactivation of APC leads to activation of the Wnt/beta-catenin pathway, which is thought to play a role in the adenoma-carcinoma transition in some cancers, including colorectal cancer (CRC)[143]. The prognostic significance of APC mutations in sporadic CRC remains unclear[144]. Solid tumors with WNT/beta-catenin pathway alterations, as seen here, were observed to have significantly less T-cell inflammation in one study[145].

FINDING SUMMARY

APC (adenomatous polyposis coli) encodes a tumor suppressor with critical roles in regulating cell division and adhesion. APC interacts with beta-catenin and controls signaling in the WNT pathway, which regulates embryonic development and cell differentiation[146]. Alterations such as seen here may disrupt APC function or expression[147-151].

POTENTIAL GERMLINE IMPLICATIONS

One or more of the APC variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with familial adenomatous polyposis (ClinVar, Sep 2021)[152]. Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in APC are found in more than 90% of patients with familial adenomatous polyposis (FAP)[153-155]. The prevalence for FAP in the general population is estimated to be 1:8,300 from birth[156], and in the appropriate clinical context germline testing of APC is recommended.

GENE
PIK3CA

ALTERATION
E545K

TRANSCRIPT ID
NM_006218

CODING SEQUENCE EFFECT
1633G>A

VARIANT ALLELE FREQUENCY (% VAF)
27.4%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Clinical and preclinical data in various tumor types indicate that PIK3CA activating alterations may predict sensitivity to therapies targeting PI3K[157-159], AKT[160-161], or mTOR[162-169]. Emerging evidence suggests that the glutaminase inhibitor telaglenastat has clinical activity in PIK3CA-mutated colorectal cancer (CRC). A Phase 1 trial of telaglenastat and capecitabine for patients with CRC who progressed on fluoropyrimidine chemotherapy observed numerically increased median PFS for patients with PIK3CA mutation compared with patients with wildtype PIK3CA status (24.8 vs. 16 weeks, n=7 vs. n=4), including SD >30 weeks for 3 patients with PIK3CA mutation[170].

— Potential Resistance —

Multiple clinical studies report that inhibitors of the PI3K-AKT-mTOR pathway have not produced significant clinical benefit as monotherapies to treat CRC, even for tumors that harbor alterations in PIK3CA or PTEN; data are more limited for alterations in other genes in this pathway[166,171-172].

FREQUENCY & PROGNOSIS

PIK3CA mutations have been reported in 10-20% of colorectal cancers[21,96,173-174]. A meta-analysis of 864 patients with colorectal cancer treated with cetuximab- or panitumumab-based therapy showed that PIK3CA mutations, particularly in exon 20 (H1047R), are significantly associated with worse response[175] and shorter progression-free and overall survival[133].

FINDING SUMMARY

PIK3CA encodes p110-alpha, which is the catalytic subunit of phosphatidylinositol 3-kinase (PI3K). The PI3K pathway is involved in cell signaling that regulates a number of critical cellular functions, including cell growth, proliferation, differentiation, motility, and survival[176-177]. PIK3CA alterations that have been characterized as activating, such as observed here, are predicted to be oncogenic[178-199].

Electronically signed by Erik Williams, M.D. | 10 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
CDKN2A/B

ALTERATION
CDKN2B loss, CDKN2A loss

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib[200-203]. Although case studies have reported that patients with breast cancer or uterine leiomyosarcoma harboring CDKN2A loss responded to palbociclib treatment[204-205], multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents[206-212]; it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors[213-214], the clinical relevance of p14ARF as a predictive biomarker is not clear. There are no drugs that directly target the mutation or loss of CDKN2B in cancer. Because the p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, tumors with CDKN2B mutation or loss may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib[207,209-210,215-217].

FREQUENCY & PROGNOSIS

Homozygous deletion of both CDKN2A and CDKN2B has been found in 1% of colorectal adenocarcinomas[21,218]. Inactivation of CDKN2A and CDKN2B by promoter methylation, also leading to loss of p15INK4b and p16INK4a expression, has been reported in colorectal adenocarcinoma[219-220]. p16INK4a expression status has not been associated with patient prognosis in colorectal adenocarcinoma[219,221].

FINDING SUMMARY

CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b[222-223]. Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth-suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6-cyclin-Rb pathway and loss of cell cycle control[224-225]. The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition[226-227]. One or more alterations observed here are predicted to result in p16INK4a loss of function[228-249]. One or more alterations seen here are predicted to result in p14ARF loss of function[232,249-252]. CDKN2B alterations such as seen here are predicted to inactivate p15INK4b[253].

POTENTIAL GERMLINE IMPLICATIONS

Germline CDKN2A mutation is associated with melanoma-pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer[254]. Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma[255-256]. CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases[257-259]. CDKN2A alteration has also been implicated in familial melanoma-astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors[260-262]. In the appropriate clinical context, germline testing of CDKN2A is recommended.

GENE
SMAD4

ALTERATION
E538*

TRANSCRIPT ID
NM_005359

CODING SEQUENCE EFFECT
1612G>T

VARIANT ALLELE FREQUENCY (% VAF)
81.9%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no therapies to address SMAD4 alterations in cancer. Preclinical studies[263-264] and a clinical study of pancreatic cancer suggest that low SMAD4 expression exhibit increased responsiveness to chemotherapeutic agents such as cisplatin and irinotecan[265].

FREQUENCY & PROGNOSIS

SMAD4 mutation or homozygous deletion is most frequently observed in pancreatic adenocarcinoma (43%)[266], pancreatic acinar cell carcinoma[267], cholangiocarcinoma (25%)[268], appendiceal adenocarcinoma (14-20% mutation; 57% deletion)[269-270], colorectal adenocarcinoma (CRC; 14%)[21], esophageal adenocarcinoma (14%)[271], and stomach adenocarcinoma (13%)[272]. In preclinical studies, SMAD4 loss of function has been implicated in the development of mucinous neoplasms of the pancreas, including mucinous cystic neoplasms (MCN)[273] and intraductal papillary mucinous neoplasms (IPMN)[274]; in clinical samples, SMAD4 homozygous deletion has been observed in 10% of IPMNs and 8% of MCNs, and mutation was also observed in 5% of IPMNs[275]. SMAD4 gene alterations have been associated with reduced overall survival for patients with pancreatic adenocarcinoma[276]. Reduced SMAD4 expression has been associated with worse prognosis in various cancer types, including CRC[277-279], appendiceal mucinous neoplasm[280], gastric adenocarcinoma[281-282], esophageal adenocarcinoma[283], esophageal squamous cell carcinoma[284], breast cancer[285], and prostate cancer[286].

FINDING SUMMARY

SMAD4, also known as DPC4, encodes a tumor suppressor that regulates transcriptional activity downstream of TGF-beta receptor signaling[287-288]. SMAD4 alterations that result in loss or disruption of the MH1 domain (aa 18-142), MH2 domain (aa 323-552), or SAD domain (aa 275-320) are predicted to be inactivating[289-302].

POTENTIAL GERMLINE IMPLICATIONS

Germline SMAD4 mutations, including those at the R361 hotspot, have been observed in patients with juvenile polyposis syndrome[303-305], which is associated with an increased risk of gastrointestinal cancers[306]. The penetrance of deleterious SMAD4 mutations in patients with colon cancer is estimated at 20% by age 35 and 70% by age 65[307]. In the appropriate clinical context, germline testing of SMAD4 is recommended.

GENE
SOX9

ALTERATION
Q411*

TRANSCRIPT ID
NM_000346

CODING SEQUENCE EFFECT
1231C>T

VARIANT ALLELE FREQUENCY (% VAF)
53.7%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no therapies available to directly address genomic alterations in SOX9.

FREQUENCY & PROGNOSIS

Mutation of SOX9 in cancer is typically rare, but it has been reported in 3-11% of colorectal carcinomas, most of which were truncating or frameshift alterations, and fewer than 4% of other tumor types (cBioPortal, COSMIC, Jan 2022)[308-310].

Increased expression of SOX9 has been associated with tumor development and/or increased aggressiveness of prostate cancer, pancreatic ductal adenocarcinoma, ovarian cancer, glioma, and esophageal adenocarcinoma[311-314].

FINDING SUMMARY

SOX9 encodes a transcription factor important for the development and differentiation of multiple tissues, including cartilage, testis, and prostate[315].

Electronically signed by Erik Williams, M.D. | 10 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

Cetuximab

Resistance of variant(s) to associated therapy is likely

Assay findings association

KRAS
G12D

NRAS
wildtype

AREAS OF THERAPEUTIC USE

Cetuximab is a monoclonal antibody that targets EGFR. It is FDA approved for the treatment of head and neck squamous cell carcinoma (HNSCC) and KRAS-wild-type, EGFR-expressing metastatic colorectal cancer (CRC). Please see the drug label for full prescribing information.

GENE ASSOCIATION

Therapies targeting EGFR, including cetuximab, have been shown to have significant clinical activity for patients with CRC[88-91,316-317] ; wild-type KRAS and NRAS are predictive biomarkers for the efficacy of cetuximab in metastatic CRC (NCCN Colon Cancer Guidelines v3.2021). Activating mutations in either KRAS[88-91] or NRAS[133,318] , which function downstream of EGFR, are associated with lack of benefit of cetuximab for patients with CRC and indicate against the use of cetuximab (NCCN Guidelines v3.2021).

SUPPORTING DATA

Cetuximab has been shown to improve OS, PFS, and response rate for patients with KRAS-wild-type CRC, both as first-line combination therapy with FOLFIRI or FOLFOX4[88-89,317] and as monotherapy or combination therapy with irinotecan for chemotherapy-refractory patients[90-91,316] . A prospective study of first-line cetuximab for patients with KRAS/NRAS/BRAF mutation-negative metastatic CRC resulted in limited efficacy, with 10.5% (2/19) of participants experiencing PRs and 57.9% (11/19) experiencing SDs[319]. The Phase 2 AVETUX trial of cetuximab combined with avelumab and mFOLFOX6 for patients with RAS- and BRAF-wild-type metastatic CRC resulted in an ORR of 79.5% (6 CR and 25 PRs, n=39) and a DCR of 92.3%[320]. In the Phase 3 ASPECCT study, panitumumab was found to be non-inferior to cetuximab with respect to median OS (10.4 vs. 10.0 months, HR=0.97) for patients with previously treated KRAS exon 2 wildtype metastatic colorectal cancer; median PFS was also similar between the two treatment groups (4.4 vs. 4.1 months, HR=1.00)[321]. In a similar patient population, a Phase 2 study of combination panitumumab and irinotecan versus combination cetuximab and irinotecan also demonstrated non-inferiority with respect to median PFS (5.4 vs. 4.3 months, HR = 0.64) and median OS (14.9 vs. 11.5 months, HR=0.66)[322].

Panitumumab

Resistance of variant(s) to associated therapy is likely

Assay findings association

KRAS
G12D

NRAS
wildtype

AREAS OF THERAPEUTIC USE

Panitumumab is a monoclonal antibody that targets EGFR. It is FDA approved to treat KRAS wild-type and NRAS wild-type metastatic colorectal cancer (CRC) combined with chemotherapy or as monotherapy for patients who have progressed on prior chemotherapy. Please see the drug label for full prescribing information.

GENE ASSOCIATION

Therapies targeting EGFR, including panitumumab, have been shown to have significant clinical activity for patients with CRC[92,321,323] ; wild-type KRAS and NRAS are predictive biomarkers for the efficacy of panitumumab in metastatic CRC (NCCN Colon Cancer Guidelines v3.2021). Activating mutations in either KRAS[92-94] or NRAS[93,324] , which function downstream of EGFR, are associated with lack of benefit of panitumumab for patients with CRC and indicate against the use of panitumumab (NCCN Guidelines v3.2021).

SUPPORTING DATA

Panitumumab has been shown to improve OS, PFS, and ORR for patients with KRAS wild-type CRC, both as first-line combination therapy with FOLFOX4[92] and as monotherapy for chemotherapy-refractory patients[321,323] . An open-label, randomized Phase 2 trial reported that for patients with unresectable RAS-wild-type colorectal adenocarcinoma treated with first-line panitumumab plus FOLFOX4, maintenance with a combination of panitumumab plus fluorouracil and leucovorin was superior to panitumumab monotherapy (10-month PFS 59% vs. 49%)[325]. In the Phase 3 ASPECCT study, panitumumab was found to be non-inferior to cetuximab with respect to median OS (10.4 vs. 10.0 months, HR=0.97) for patients with previously treated KRAS exon 2 wildtype metastatic colorectal cancer; median PFS was also similar between the two treatment groups (4.4 vs. 4.1 months, HR=1.00)[321]. In a similar patient population, a Phase 2 study of combination panitumumab and irinotecan versus combination cetuximab and irinotecan also demonstrated non-inferiority with respect to median PFS (5.4 vs. 4.3 months, HR = 0.64) and median OS (14.9 vs. 11.5 months, HR=0.66)[322].

NOTE Genomic alterations detected may be associated with activity of certain FDA approved drugs, however, the agents listed in this report may have varied evidence in the patient's tumor type.

Electronically signed by Erik Williams, M.D. | 10 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

NOTE Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials listed here may have additional enrollment criteria that may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. Or visit https://www.foundationmedicine.com/genomic-testing#support-services.

GENE
APC

ALTERATION
T1556fs*3

RATIONALE
Based on preclinical and limited clinical data, APC inactivation may be associated with sensitivity to CBP/beta-catenin interaction inhibitors.

NCT03833700

PHASE 1

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

TARGETS
CBP, Beta-catenin

LOCATIONS: Fukuoka (Japan), Nagaizumi-cho (Japan), Chuo Ku (Japan), Kashiwa (Japan)

NCT05091346

PHASE 1/2

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

TARGETS
CBP, Beta-catenin, PD-1

LOCATIONS: Tokyo (Japan)

NCT04008797

PHASE 1

A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor

TARGETS
CBP, Beta-catenin, FGFRs, RET, PDGFRA, VEGFRs, KIT

LOCATIONS: Osakasayama (Japan), Chuo-Ku (Japan), Kashiwa (Japan)

NCT03264664

PHASE 1

Study of E7386 in Participants With Selected Advanced Neoplasms

TARGETS
CBP, Beta-catenin

LOCATIONS: Glasgow (United Kingdom), Manchester (United Kingdom), Sutton (United Kingdom)

GENE
KRAS

ALTERATION
G12D

RATIONALE
KRAS activating mutations or amplification may predict sensitivity to inhibitors of MAPK pathway components, including MEK inhibitors. KRAS mutation may predict sensitivity to PLK1 inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK-pan-RAF dual inhibitors. Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS-mutant colorectal cancer; combination therapies may be more effective.

NCT04803318

PHASE 2

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

TARGETS
mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK

LOCATIONS: Guangzhou (China)

NCT03284502

PHASE 1

Cobimetinib and HM95573 in Patients With Locally Advanced or Metastatic Solid Tumors

TARGETS
MEK, RAFs

LOCATIONS: Hwasun (Korea, Republic of), Pusan (Korea, Republic of), Seongnam (Korea, Republic of), Seoul (Korea, Republic of), Goyang-si (Korea, Republic of)

NCT04303403

PHASE 1

Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma

TARGETS
JAK2, JAK1, MEK

LOCATIONS: Singapore (Singapore)

NCT04801966

PHASE NULL

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

TARGETS
CDK4, CDK6, PI3K-alpha, PD-L1, MEK, PARP, PD-1, BRAF

LOCATIONS: Melbourne (Australia)

NCT03905148

PHASE 1/2

Study of the Safety and Pharmacokinetics of BGB-283 and PD-0325901 in Patients With Advanced or Refractory Solid Tumors

TARGETS
RAFs, EGFR, MEK

LOCATIONS: Nedlands (Australia), Blacktown (Australia), Randwick (Australia), Melbourne (Australia), California, Texas

NCT02079740

PHASE 1/2

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

TARGETS
BCL2, BCL-XL, BCL-W, MEK

LOCATIONS: Massachusetts

NCT02613650

PHASE 1

A Trial of mFOLFIRI With MEK162 in Patients With Advanced KRAS Positive Metastatic Colorectal Cancers

TARGETS MEK

LOCATIONS: Utah

NCT04965818

PHASE 1/2

Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

TARGETS MEK, FGFRs

LOCATIONS: California, Indiana, Texas

NCT03829410

PHASE 1/2

Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation

TARGETS PLK1, VEGFA

LOCATIONS: California, Arizona, Minnesota, Kansas, Arkansas, Virginia, Florida

NCT04800822

PHASE 1

PF-07284892 in Participants With Advanced Solid Tumors

TARGETS SHP2, ROS1, ALK, MEK, BRAF, EGFR

LOCATIONS: California, Michigan, New York, Tennessee, Texas

Electronically signed by Erik Williams, M.D. | 10 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
PIK3CA

ALTERATION
E545K

RATIONALE
PIK3CA activating mutations may lead to activation of the PI3K-AKT-mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA-mutated solid tumors to the PI3K-alpha inhibitor alpelisib. Several clinical studies have shown that inhibitors of the PI3K-AKT-mTOR pathway have not produced significant clinical benefit when used as a monotherapy in patients with colorectal cancer; combination therapies may be required to overcome this lack of response. On the basis of preclinical and limited clinical data, PIK3CA activating mutations may predict sensitivity to glutaminase inhibitors.

NCT04589845

PHASE 2

Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

TARGETS
TRKB, ALK, TRKC, ROS1, TRKA, RET, PD-L1, AKTs, ERBB2, MDM2, PI3K-alpha

LOCATIONS: Zhongzheng Dist. (Taiwan), Taipei City (Taiwan), Taoyuan County (Taiwan), Tainan (Taiwan), Hong Kong (Hong Kong), Seoul (Korea, Republic of), Xi'an (China), Tianjin (China), Beijing (China), Chengdu City (China)

NCT04337463

PHASE NULL

ATG-008 Combined With Toripalimab in Advanced Solid Tumors

TARGETS
mTORC1, mTORC2, PD-1

LOCATIONS: Chongqing (China), Chengdu (China)

NCT04803318

PHASE 2

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

TARGETS
mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK

LOCATIONS: Guangzhou (China)

NCT03772561

PHASE 1

Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies

TARGETS
PARP, AKTs, PD-L1

LOCATIONS: Singapore (Singapore)

NCT04801966

PHASE NULL

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

TARGETS
CDK4, CDK6, PI3K-alpha, PD-L1, MEK, PARP, PD-1, BRAF

LOCATIONS: Melbourne (Australia)

NCT03711058

PHASE 1/2

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

TARGETS PD-1, PI3K

LOCATIONS: Maryland

NCT03006172

PHASE 1

To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

TARGETS PI3K-alpha, Aromatase, ER, CDK6, CDK4

LOCATIONS: London (United Kingdom), Surrey (United Kingdom), Bordeaux (France), Barcelona (Spain), Valencia (Spain), Toronto (Canada), Massachusetts, New York, Tennessee

NCT03673787

PHASE 1/2

A Trial of Ipatasertib in Combination With Atezolizumab

TARGETS AKTs, PD-L1

LOCATIONS: Sutton (United Kingdom)

NCT03065062

PHASE 1

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

TARGETS PI3K-alpha, PI3K-gamma, mTORC1, mTORC2, CDK4, CDK6

LOCATIONS: Massachusetts

NCT03217669

PHASE 1

Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy

TARGETS IDO1, mTOR

LOCATIONS: Kansas

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

AR
S176R

BCOR
V878A

BCORL1
V872G

BRIP1
N775S

FLT3
N484S

INPP4B
Y919N

JAK1
S537G

PARP3
R408H

ROS1
D2213E and Q1708L

SPEN
N2999K and T796S

TIPARP
G307*

Electronically signed by Erik Williams, M.D. | 10 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

APPENDIX Genes Assayed in FoundationOne®CDx

FoundationOne CDx is designed to include genes known to be somatically altered in human solid tumors that are validated targets for therapy, either approved or in clinical trials, and/or that are unambiguous drivers of oncogenesis based on current knowledge. The current assay interrogates 324 genes as well as introns of 36 genes involved in rearrangements. The assay will be updated periodically to reflect new knowledge about cancer biology.

DNA GENE LIST: ENTIRE CODING SEQUENCE FOR THE DETECTION OF BASE SUBSTITUTIONS, INSERTION/DELETIONS, AND COPY NUMBER ALTERATIONS

ABL1	*ACVR1B*	*AKT1*	*AKT2*	*AKT3*	*ALK*	*ALOX12B*	*AMER1 (FAM123B)*	*APC*
AR	*ARAF*	*ARFRP1*	*ARID1A*	*ASXL1*	*ATM*	*ATR*	*ATRX*	*AURKA*
AURKB	*AXIN1*	*AXL*	*BAP1*	*BARD1*	*BCL2*	*BCL2L1*	*BCL2L2*	*BCL6*
BCOR	*BCORL1*	*BRAF*	*BRCA1*	*BRCA2*	*BRD4*	*BRIP1*	*BTG1*	*BTG2*
BTK	*C11orf30 (EMSY)*	*C17orf39 (GID4)*	*CALR*	*CARD11*	*CASP8*	*CBFB*	*CBL*	*CCND1*
CCND2	*CCND3*	*CCNE1*	*CD22*	*CD274 (PD-L1)*	*CD70*	*CD79A*	*CD79B*	*CDC73*
CDH1	*CDK12*	*CDK4*	*CDK6*	*CDK8*	*CDKN1A*	*CDKN1B*	*CDKN2A*	*CDKN2B*
CDKN2C	*CEBPA*	*CHEK1*	*CHEK2*	*CIC*	*CREBBP*	*CRKL*	*CSF1R*	*CSF3R*
CTCF	*CTNNA1*	*CTNNB1*	*CUL3*	*CUL4A*	*CXCR4*	*CYP17A1*	*DAXX*	*DDR1*
DDR2	*DIS3*	*DNMT3A*	*DOT1L*	*EED*	*EGFR*	*EP300*	*EPHA3*	*EPHB1*
EPHB4	*ERBB2*	*ERBB3*	*ERBB4*	*ERCC4*	*ERG*	*ERRFI1*	*ESR1*	*EZH2*
FAM46C	*FANCA*	*FANCC*	*FANCG*	*FANCL*	*FAS*	*FBXW7*	*FGF10*	*FGF12*
FGF14	*FGF19*	*FGF23*	*FGF3*	*FGF4*	*FGF6*	*FGFR1*	*FGFR2*	*FGFR3*
FGFR4	*FH*	*FLCN*	*FLT1*	*FLT3*	*FOXL2*	*FUBP1*	*GABRA6*	*GATA3*
GATA4	*GATA6*	*GNA11*	*GNA13*	*GNAQ*	*GNAS*	*GRM3*	*GSK3B*	*H3F3A*
HDAC1	*HGF*	*HNF1A*	*HRAS*	*HSD3B1*	*ID3*	*IDH1*	*IDH2*	*IGF1R*
IKBKE	*IKZF1*	*INPP4B*	*IRF2*	*IRF4*	*IRS2*	*JAK1*	*JAK2*	*JAK3*
JUN	*KDM5A*	*KDM5C*	*KDM6A*	*KDR*	*KEAP1*	*KEL*	*KIT*	*KLHL6*
KMT2A (MLL)	*KMT2D (MLL2)*	*KRAS*	*LTK*	*LYN*	*MAF*	*MAP2K1 (MEK1)*	*MAP2K2 (MEK2)*	*MAP2K4*
MAP3K1	*MAP3K13*	*MAPK1*	*MCL1*	*MDM2*	*MDM4*	*MED12*	*MEF2B*	*MEN1*
MERTK	*MET*	*MITF*	*MKNK1*	*MLH1*	*MPL*	*MRE11A*	*MSH2*	*MSH3*
MSH6	*MST1R*	*MTAP*	*MTOR*	*MUTYH*	*MYC*	*MYCL (MYCL1)*	*MYCN*	*MYD88*
NBN	*NF1*	*NF2*	*NFE2L2*	*NFKBIA*	*NKX2-1*	*NOTCH1*	*NOTCH2*	*NOTCH3*
NPM1	*NRAS*	*NSD3 (WHSC1L1)*	*NT5C2*	*NTRK1*	*NTRK2*	*NTRK3*	*P2RY8*	*PALB2*
PARK2	*PARP1*	*PARP2*	*PARP3*	*PAX5*	*PBRM1*	*PDCD1 (PD-1)*	*PDCD1LG2 (PD-L2)*	*PDGFRA*
PDGFRB	*PDK1*	*PIK3C2B*	*PIK3C2G*	*PIK3CA*	*PIK3CB*	*PIK3R1*	*PIM1*	*PMS2*
POLD1	*POLE*	*PPARG*	*PPP2R1A*	*PPP2R2A*	*PRDM1*	*PRKAR1A*	*PRKCI*	*PTCH1*
PTEN	*PTPN11*	*PTPRO*	*QKI*	*RAC1*	*RAD21*	*RAD51*	*RAD51B*	*RAD51C*
RAD51D	*RAD52*	*RAD54L*	*RAF1*	*RARA*	*RB1*	*RBM10*	*REL*	*RET*
RICTOR	*RNF43*	*ROS1*	*RPTOR*	*SDHA*	*SDHB*	*SDHC*	*SDHD*	*SETD2*
SF3B1	*SGK1*	*SMAD2*	*SMAD4*	*SMARCA4*	*SMARCB1*	*SMO*	*SNCAIP*	*SOCS1*
SOX2	*SOX9*	*SPEN*	*SPOP*	*SRC*	*STAG2*	*STAT3*	*STK11*	*SUFU*
SYK	*TBX3*	*TEK*	*TET2*	*TGFBR2*	*TIPARP*	*TNFAIP3*	*TNFRSF14*	*TP53*
TSC1	*TSC2*	*TYRO3*	*U2AF1*	*VEGFA*	*VHL*	*WHSC1*	*WT1*	*XPO1*
XRCC2	*ZNF217*	*ZNF703*						

DNA GENE LIST: FOR THE DETECTION OF SELECT REARRANGEMENTS

ALK	*BCL2*	*BCR*	*BRAF*	*BRCA1*	*BRCA2*	*CD74*	*EGFR*	*ETV4*
ETV5	*ETV6*	*EWSR1*	*EZR*	*FGFR1*	*FGFR2*	*FGFR3*	*KIT*	*KMT2A (MLL)*
MSH2	*MYB*	*MYC*	*NOTCH2*	*NTRK1*	*NTRK2*	*NUTM1*	*PDGFRA*	*RAF1*
RARA	*RET*	*ROS1*	*RSPO2*	*SDC4*	*SLC34A2*	*TERC**	*TERT***	*TMPRSS2*

*TERC is an NCRNA

**Promoter region of TERT is interrogated

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Loss of Heterozygosity (LOH) score
Microsatellite (MS) status
Tumor Mutational Burden (TMB)

Electronically signed by Erik Williams, M.D. | 10 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

FoundationOne CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium. CE

ABOUT FOUNDATIONONE CDX

FoundationOne CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details: www.rochefoundationmedicine.com/f1cdxtech.

INTENDED USE

FoundationOne®CDx (F1CDx) is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI), tumor mutational burden (TMB), and for selected forms of ovarian cancer, loss of heterozygosity (LOH) score, using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with therapies in accordance with approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms.

TEST PRINCIPLES

FoundationOne CDx will be performed exclusively as a laboratory service using DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor samples. The proposed assay will employ a single DNA extraction method from routine FFPE biopsy or surgical resection specimens, 50-1000 ng of which will undergo whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, one promoter region, one non-coding (ncRNA), and select intronic regions from 34 commonly rearranged genes, 21 of which also include the coding exons. The assay therefore includes detection of alterations in a total of 324 genes.

Using an Illumina® HiSeq platform, hybrid capture–selected libraries will be sequenced to high uniform depth (targeting >500X median coverage with >99% of exons at coverage >100X). Sequence data will be processed using a customized analysis pipeline designed to accurately detect all classes of genomic alterations, including base substitutions, indels, focal copy number amplifications, homozygous gene deletions, and selected genomic rearrangements (e.g.,gene fusions). Additionally, genomic signatures including loss of heterozygosity (LOH), microsatellite instability (MSI) and tumor mutational burden (TMB) will be reported.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. The F1CDx report may be used as an aid to inform molecular eligibility for clinical trials. Note: A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

Diagnostic Significance

FoundationOne CDx identifies alterations to select cancer-associated genes or portions of genes (biomarkers). In some cases, the Report also highlights selected negative test results regarding biomarkers of clinical significance.

Qualified Alteration Calls (Equivocal and Subclonal)

An alteration denoted as "amplification – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence that the copy number of a gene exceeds the threshold for identifying copy number amplification. The threshold used in FoundationOne CDx for identifying a copy number amplification is four (4) for ERBB2 and six (6) for all other genes. Conversely, an alteration denoted as "loss – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence for homozygous deletion of the gene in question. An alteration denoted as "subclonal" is one that the FoundationOne CDx analytical methodology has identified as being present in <10% of the assayed tumor DNA.

Ranking of Therapies and Clinical Trials

Ranking of Therapies in Summary Table

Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Limitations

1. In the fractional-based MSI algorithm, a tumor specimen will be categorized as MSI-H, MSS, or MS-Equivocal according to the fraction of microsatellite loci determined to be altered or unstable (i.e., the fraction unstable loci score). In the F1CDx assay, MSI is evaluated based on a genome-wide analysis across >2000 microsatellite loci. For a given microsatellite locus, non-somatic alleles are discarded, and the microsatellite is categorized as unstable if remaining alleles differ from the reference genome. The final fraction unstable loci score is calculated as the number of unstable microsatellite loci divided by the number of evaluable microsatellite loci. The MSI-H and MSS cut-off thresholds were determined by analytical concordance to a PCR comparator assay using a pan-tumor FFPE tissue sample set. Patients with results categorized as "MS-

Stable" with median exon coverage <300X, "MS-Equivocal," or "Cannot Be Determined" should receive confirmatory testing using a validated orthogonal (alternative) method.

2. TMB by F1CDx is determined by counting all synonymous and non-synonymous variants present at 5% allele frequency or greater (after filtering) and the total number is reported as mutations per megabase (mut/Mb) unit. Observed TMB is dependent on characteristics of the specific tumor focus tested for a patient (e.g., primary vs. metastatic, tumor content) and the testing platform used for the detection; therefore, observed TMB results may vary between different specimens for the same patient and between detection methodologies employed on the same sample. The TMB calculation may differ from TMB calculations used by other assays depending on variables such as the amount of genome interrogated, percentage of tumor, assay limit of detection (LoD), filtering of alterations included in the score, and the read depth and other bioinformatic test specifications. Refer to the SSED for a detailed description of these variables in FMI's TMB calculation https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf. The clinical validity of TMB defined by this panel has been established for TMB as a qualitative output for a cut-off of 10 mutations per megabase but has not been established for TMB as a quantitative score.
3. The LOH score is determined by analyzing SNPs spaced at 1Mb intervals across the genome on the FoundationOne CDx test and extrapolating an LOH profile, excluding arm- and chromosome-wide LOH segments. Detection of LOH has been verified only for ovarian cancer patients, and the LOH score result may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas. The LOH score will be reported as "Cannot Be Determined" if the sample is not of sufficient quality to confidently determine LOH. Performance of the LOH classification has not been established for samples below 35% tumor content. There may be potential interference of ethanol with LOH detection. The interfering effects of xylene, hemoglobin, and triglycerides on the LOH score have not been demonstrated.
4. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. The test does not provide information about susceptibility.
5. Biopsy may pose a risk to the patient when archival tissue is not available for use with the assay. The patient's physician should determine whether the patient is a candidate for biopsy.
6. Reflex testing to an alternative FDA approved companion diagnostic should be performed for patients who have an *ERBB2* amplification result detected with copy number equal to 4 (baseline ploidy of tumor +2) for confirmatory testing. While this result is considered negative by FoundationOne®CDx (F1CDx), in a clinical concordance study with an FDA approved FISH test, 70% (7 out of 10 samples) were positive, and 30% (3 out of 10 samples) were negative by the FISH test with an average ratio of 2.3. The frequency of *ERBB2* copy number 4 in breast cancer is estimated to be approximately 2%. Multiple references listed in https://www.mycancergenome.org/content/disease/breast-cancer/ERBB2/238/ report the frequency of HER2 overexpression as 20% in breast cancer. Based on the F1CDx HER2 CDx concordance study, approximately 10% of HER2 amplified samples had copy number 4. Thus, total frequency is conservatively estimated to be approximately 2%.

REPORT HIGHLIGHTS

The Report Highlights includes select genomic and therapeutic information with potential impact on patient care and treatment that is specific to the genomics and tumor type of the sample analyzed. This section may highlight information including targeted therapies with potential sensitivity or resistance; evidence-matched clinical trials; and variants with potential diagnostic, prognostic, nontargeted treatment, germline, or clonal hematopoiesis implications. Information included in the Report Highlights is expected to evolve with advances in scientific and clinical research. Findings included in the Report Highlights should be considered in the context of all other information in this report and other relevant patient information. Decisions on patient care and treatment are the responsibility of the treating physician.

VARIANT ALLELE FREQUENCY

Variant Allele Frequency (VAF) represents the fraction of sequencing reads in which the variant is observed. This attribute is not taken into account for therapy inclusion, clinical trial matching, or interpretive content. Caution is recommended in interpreting VAF to indicate the potential germline or somatic origin of an alteration, recognizing that tumor fraction and tumor ploidy of samples may vary.

Precision of VAF for base substitutions and indels

BASE SUBSTITUTIONS	%CV*
Repeatability	5.11 - 10.40
Reproducibility	5.95 - 12.31
INDELS	**%CV***
Repeatability	6.29 - 10.00
Reproducibility	7.33 - 11.71

**Interquartile Range = 1st Quartile to 3rd Quartile*

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >10%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM, BAP1, BRCA1, BRCA2, BRIP1, CHEK2, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLE, RAD51C, RAD51D, RET, SDHA, SDHB, SDHC, SDHD, TSC2,* and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1, CBL, DNMT3A, IDH2, JAK2, KMT2D (MLL2), MPL, MYD88, SF3B1, TET2,* and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear

cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This Report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This Report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne CDx.

TREATMENT DECISIONS ARE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this Test, or the information contained in this Report. Certain sample or variant characteristics may result in reduced sensitivity. FoundationOne CDx is performed using DNA derived from tumor, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

MR Suite Version 6.0.0

The median exon coverage for this sample is 1,030x

Electronically signed by Erik Williams, M.D. | 10 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

1. Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179
2. Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250
3. Lal N, et al. Oncoimmunology (2015) pmid: 25949894
4. Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255
5. Ayers et al., 2016; ASCO-SITC Abstract P60
6. Ciardiello et al., 2018; ESMO Abstract LBA-004
7. Parikh et al., 2021; DOI: 10.1038/s43018-021-00269-7
8. Fukuoka S, et al. J. Clin. Oncol. (2020) pmid: 32343640
9. Kim et al., 2020; DOI: 10.1016/j.annonc.2020.04.073
10. Zhang Y, et al. BMC Gastroenterol (2021) pmid: 34688262
11. Sinicrope FA, et al. J. Clin. Oncol. (2013) pmid: 24019539
12. Gavin PG, et al. Clin. Cancer Res. (2012) pmid: 23045248
13. Bertagnolli MM, et al. J. Clin. Oncol. (2009) pmid: 19273709
14. Van Cutsem E, et al. J. Clin. Oncol. (2009) pmid: 19451425
15. Ribic CM, et al. N. Engl. J. Med. (2003) pmid: 12867608
16. Sargent DJ, et al. J. Clin. Oncol. (2010) pmid: 20498393
17. Fallik D, et al. Cancer Res. (2003) pmid: 14522894
18. Guastadisegni C, et al. Eur. J. Cancer (2010) pmid: 20627535
19. Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785
20. Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942
21. Nature (2012) pmid: 22810696
22. Histopathology (2007) pmid: 17204026
23. Samowitz WS, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11535541
24. Elsaleh H, et al. Clin Colorectal Cancer (2001) pmid: 12445368
25. Brueckl WM, et al. Anticancer Res. () pmid: 12820457
26. Guidoboni M, et al. Am. J. Pathol. (2001) pmid: 11438476
27. Gryfe R, et al. N. Engl. J. Med. (2000) pmid: 10631274
28. Sinicrope FA, et al. Gastroenterology (2006) pmid: 16952542
29. Laghi L, et al. Dig Dis (2012) pmid: 22722556
30. You JF, et al. Br. J. Cancer (2010) pmid: 21081928
31. Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249
32. Boland CR, et al. Cancer Res. (1998) pmid: 9823339
33. Boland CR, et al. Gastroenterology (2010) pmid: 20420947
34. Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254
35. Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386
36. Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947
37. Cristescu R, et al. Science (2018) pmid: 30309915
38. Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829
39. Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845
40. Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128
41. Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394
42. Rozeman EA, et al. Nat Med (2021) pmid: 33558721
43. Sharma P, et al. Cancer Cell (2020) pmid: 32916128
44. Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526
45. Legrand et al., 2018; ASCO Abstract 12000
46. Fabrizio DA, et al. J Gastrointest Oncol (2018) pmid: 30151257
47. Stadler ZK, et al. J. Clin. Oncol. (2016) pmid: 27022117
48. Shao C, et al. JAMA Netw Open (2020) pmid: 33119110
49. Chen EX, et al. JAMA Oncol (2020) pmid: 32379280
50. Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635
51. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803
52. Pfeifer GP, et al. Oncogene (2002) pmid: 12379884
53. Rizvi NA, et al. Science (2015) pmid: 25765070
54. Johnson BE, et al. Science (2014) pmid: 24336570
55. Choi S, et al. Neuro-oncology (2018) pmid: 29452419
56. Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398
57. Briggs S, et al. J. Pathol. (2013) pmid: 23447401
58. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393
59. Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919
60. Nakano H, et al. Proc. Natl. Acad. Sci. U.S.A. (1984) pmid: 6320174
61. Pylayeva-Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244
62. Yamaguchi T, et al. Int. J. Oncol. (2011) pmid: 21523318
63. Watanabe M, et al. Cancer Sci. (2013) pmid: 23438367
64. Gilmartin AG, et al. Clin. Cancer Res. (2011) pmid: 21245089
65. Yeh JJ, et al. Mol. Cancer Ther. (2009) pmid: 19372556
66. Tsimberidou et al., 2013; ASCO Abstract e22086
67. Infante JR, et al. Lancet Oncol. (2012) pmid: 22805291
68. Zimmer L, et al. Clin. Cancer Res. (2014) pmid: 24947927
69. Bennouna J, et al. Invest New Drugs (2011) pmid: 20127139
70. Weekes CD, et al. Clin. Cancer Res. (2013) pmid: 23434733
71. Hochster et al., 2013; ASCO GI Abstract 380
72. Juric et al., 2014; ASCO Abstract 9051
73. Lamba S, et al. Cell Rep (2014) pmid: 25199829
74. Sun C, et al. Cell Rep (2014) pmid: 24685132
75. Guo C, et al. Lancet Oncol (2020) pmid: 33128873
76. Krebs et al., 2021; AACR Abstract CT019
77. Shinde et al., 2020; AACR Abstract CT143
78. Lu H, et al. Mol Cancer Ther (2019) pmid: 31068384
79. Mainardi S, et al. Nat Med (2018) pmid: 29808006
80. Koczywas et al., 2021; AACR Abstract LB001
81. Bendell et al., 2020; EORTC-NCI-AACR Abstract 5
82. Hillig RC, et al. Proc Natl Acad Sci U S A (2019) pmid: 30683722
83. Hofmann MH, et al. Cancer Discov (2021) pmid: 32816843
84. Hofmann et al., 2021; AACR Abstract CT210
85. Gort et al., 2020; ASCO Abstract TPS3651
86. Luo J, et al. Cell (2009) pmid: 19490893
87. Barzi et al., 2020; AACR Abstract CT235
88. Van Cutsem E, et al. J. Clin. Oncol. (2011) pmid: 21502544
89. Bokemeyer C, et al. Ann. Oncol. (2011) pmid: 21228335
90. Karapetis CS, et al. N. Engl. J. Med. (2008) pmid: 18946061
91. De Roock W, et al. Ann. Oncol. (2008) pmid: 17998284
92. Douillard JY, et al. Ann. Oncol. (2014) pmid: 24718886
93. Douillard JY, et al. N. Engl. J. Med. (2013) pmid: 24024839
94. Amado RG, et al. J. Clin. Oncol. (2008) pmid: 18316791
95. Lièvre A, et al. Cancer Res. (2006) pmid: 16618717
96. De Roock W, et al. Lancet Oncol. (2011) pmid: 21163703
97. Chen J, et al. BMC Cancer (2014) pmid: 25367198
98. Li W, et al. BMC Cancer (2015) pmid: 25929517
99. Hu J, et al. Medicine (Baltimore) (2016) pmid: 27977612
100. Zekri J, et al. Genet. Mol. Res. (2017) pmid: 28218784
101. Staudacher JJ, et al. Clin Transl Gastroenterol (2017) pmid: 29048416
102. Wang Y, et al. Virchows Arch. (2018) pmid: 29705968
103. Guo F, et al. Sci Rep (2018) pmid: 29666387
104. Mármol I, et al. Int J Mol Sci (2017) pmid: 28106826
105. Kwak MS, et al. Medicine (Baltimore) (2017) pmid: 28858102
106. Kahn S, et al. Anticancer Res. () pmid: 3310850
107. Akagi K, et al. Biochem. Biophys. Res. Commun. (2007) pmid: 17150185
108. Bollag G, et al. J. Biol. Chem. (1996) pmid: 8955068
109. Buhrman G, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20194776
110. Sci. STKE (2004) pmid: 15367757
111. Edkins S, et al. Cancer Biol. Ther. (2006) pmid: 16969076
112. Feig LA, et al. Mol. Cell. Biol. (1988) pmid: 3043178
113. Gremer L, et al. Hum. Mutat. (2011) pmid: 20949621
114. Janakiraman M, et al. Cancer Res. (2010) pmid: 20570890
115. Kim E, et al. Cancer Discov (2016) pmid: 27147599
116. Lukman S, et al. PLoS Comput. Biol. (2010) pmid: 20838576
117. Naguib A, et al. J Mol Signal (2011) pmid: 21371307
118. Prior IA, et al. Cancer Res. (2012) pmid: 22589270
119. Privé GG, et al. Proc. Natl. Acad. Sci. U.S.A. (1992) pmid: 1565661
120. Scheffzek K, et al. Science (1997) pmid: 9219684
121. Scholl C, et al. Cell (2009) pmid: 19490892
122. Smith G, et al. Br. J. Cancer (2010) pmid: 20147967
123. Tyner JW, et al. Blood (2009) pmid: 19075190
124. Valencia A, et al. Biochemistry (1991) pmid: 2029511
125. White Y, et al. Nat Commun (2016) pmid: 26854029
126. Wiest JS, et al. Oncogene (1994) pmid: 8058307
127. Angeles AKJ, et al. Oncol Lett (2019) pmid: 31289513
128. Tong JH, et al. Cancer Biol. Ther. (2014) pmid: 24642870
129. Loree JM, et al. Clin Cancer Res (2021) pmid: 34117033
130. Pentheroudakis G, et al. BMC Cancer (2013) pmid: 23374602
131. Vaughn CP, et al. Genes Chromosomes Cancer (2011) pmid: 21305640
132. Janku F, et al. Target Oncol (2013) pmid: 23400451
133. De Roock W, et al. Lancet Oncol. (2010) pmid: 20619739
134. Irahara N, et al. Diagn. Mol. Pathol. (2010) pmid: 20736745
135. Schirripa M, et al. Int. J. Cancer (2015) pmid: 24806288
136. Cercek A, et al. Clin. Cancer Res. (2017) pmid: 28446505
137. Zhan T, et al. Oncogene (2017) pmid: 27617575
138. Jung YS, et al. Exp Mol Med (2020) pmid: 32037398
139. Krishnamurthy N, et al. Cancer Treat Rev (2018) pmid: 29169144
140. Kawazoe et al., 2021; ESMO Abstract 473P
141. Yamada K, et al. Cancer Res (2021) pmid: 33408116
142. Kanda Y, et al. Biochem Biophys Res Commun (2022) pmid: 34837838
143. Fu Y, et al. Int. J. Cancer (2011) pmid: 21455986
144. Quyn AJ, et al. Surgeon (2008) pmid: 19110823
145. Luke JJ, et al. Clin Cancer Res (2019) pmid: 30635339
146. Logan CY, et al. Annu. Rev. Cell Dev. Biol. (2004) pmid: 15473860
147. Eklof Spink K, et al. EMBO J. (2001) pmid: 11707392
148. Liu J, et al. J. Mol. Biol. (2006) pmid: 16753179
149. Dikovskaya D, et al. J. Cell. Sci. (2010) pmid: 20144988
150. Murphy SJ, et al. Dig. Dis. Sci. (2007) pmid: 17410430

Electronically signed by Erik Williams, M.D. | 10 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

151. Aretz S, et al. Hum. Mutat. (2004) pmid: 15459959
152. Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669
153. Kerr SE, et al. J Mol Diagn (2013) pmid: 23159591
154. Annu Rev Pathol (2011) pmid: 21090969
155. Kastritis E, et al. Int. J. Cancer (2009) pmid: 18844223
156. Half E, et al. Orphanet J Rare Dis (2009) pmid: 19822006
157. Fritsch C, et al. Mol. Cancer Ther. (2014) pmid: 24608574
158. Juric D, et al. J. Clin. Oncol. (2018) pmid: 29401002
159. Gallant JN, et al. NPJ Precis Oncol (2019) pmid: 30793038
160. André F, et al. N. Engl. J. Med. (2019) pmid: 31091374
161. Smyth LM, et al. NPJ Breast Cancer (2021) pmid: 33863913
162. Park HS, et al. PLoS ONE (2016) pmid: 27105424
163. Lim SM, et al. Oncotarget (2016) pmid: 26859683
164. Hou MM, et al. Oncotarget (2014) pmid: 25426553
165. Varnier R, et al. Eur J Cancer (2019) pmid: 31351267
166. Janku F, et al. Cell Rep (2014) pmid: 24440717
167. Moroney J, et al. Clin. Cancer Res. (2012) pmid: 22927482
168. Basho RK, et al. JAMA Oncol (2017) pmid: 27893038
169. Moroney JW, et al. Clin. Cancer Res. (2011) pmid: 21890452
170. Zhao Y, et al. Cancer Res (2020) pmid: 32907836
171. Ng K, et al. Clin. Cancer Res. (2013) pmid: 23743569
172. Ganesan P, et al. Mol. Cancer Ther. (2013) pmid: 24092809
173. Li HT, et al. Oncol. Rep. (2011) pmid: 21424126
174. Brannon AR, et al. Genome Biol. (2014) pmid: 25164765
175. Huang L, et al. Arch Med Sci (2014) pmid: 24701207
176. Samuels Y, et al. Cancer Cell (2005) pmid: 15950905
177. Nat. Rev. Cancer (2009) pmid: 19629070
178. Kang S, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 15647370
179. Ikenoue T, et al. Cancer Res. (2005) pmid: 15930273
180. Gymnopoulos M, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17376864
181. Horn S, et al. Oncogene (2008) pmid: 18317450
182. Rudd ML, et al. Clin. Cancer Res. (2011) pmid: 21266528
183. Hon WC, et al. Oncogene (2012) pmid: 22120714
184. Burke JE, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22949682
185. Wu H, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19915146
186. Laurenti R, et al. Rev Saude Publica (1990) pmid: 2103068
187. Dan S, et al. Cancer Res. (2010) pmid: 20530683
188. Oda K, et al. Cancer Res. (2008) pmid: 18829572
189. Zhao L, et al. Oncogene (2008) pmid: 18794883
190. Lui VW, et al. Cancer Discov (2013) pmid: 23619167
191. Ross RL, et al. Oncogene (2013) pmid: 22430209
192. Rivière JB, et al. Nat. Genet. (2012) pmid: 22729224
193. Shibata T, et al. Cancer Lett. (2009) pmid: 19394761
194. Dogruluk T, et al. Cancer Res. (2015) pmid: 26627007
195. Croessmann S, et al. Clin. Cancer Res. (2018) pmid: 29284706
196. Ng PK, et al. Cancer Cell (2018) pmid: 29533785
197. Spangle JM, et al. (2020) pmid: 32929011
198. Chen L, et al. Nat Commun (2018) pmid: 29636477
199. Jin N, et al. J Clin Invest (2021) pmid: 34779417
200. Konecny GE, et al. Clin. Cancer Res. (2011) pmid: 21278246
201. Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21871868
202. Cen L, et al. Neuro-oncology (2012) pmid: 22711607
203. Logan JE, et al. Anticancer Res. (2013) pmid: 23898052
204. Elvin JA, et al. Oncologist (2017) pmid: 28283584
205. Gao J, et al. Curr Oncol (2015) pmid: 26715889
206. Gopalan et al., 2014; ASCO Abstract 8077
207. Peguero et al., 2016; ASCO Abstract 2528
208. Konecny et al., 2016; ASCO Abstract 5557
209. DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126
210. Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798
211. Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767
212. Johnson DB, et al. Oncologist (2014) pmid: 24797823
213. Van Maerken T, et al. Mol. Cancer Ther. (2011) pmid: 21460101
214. Gamble LD, et al. Oncogene (2012) pmid: 21725357
215. Shapiro et al., 2013; ASCO Abstract 2500
216. Flaherty KT, et al. Clin. Cancer Res. (2012) pmid: 22090362
217. Dickson MA, et al. J. Clin. Oncol. (2013) pmid: 23569312
218. Giannakis M, et al. Cell Rep (2016) pmid: 27149842
219. Shima K, et al. Int. J. Cancer (2011) pmid: 20473920
220. Nieminen TT, et al. Cancer Epidemiol. Biomarkers Prev. (2012) pmid: 22028395
221. Huh JW, et al. Hepatogastroenterology () pmid: 21033219
222. Quelle DE, et al. Cell (1995) pmid: 8521522
223. Mutat. Res. (2005) pmid: 15878778
224. Gazzeri S, et al. Oncogene (1998) pmid: 9484839
225. Oncogene (1999) pmid: 10498883
226. Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) pmid: 16869746
227. Ozenne P, et al. Int. J. Cancer (2010) pmid: 20549699
228. Ruas M, et al. Oncogene (1999) pmid: 10498896
229. Jones R, et al. Cancer Res. (2007) pmid: 17909018
230. Haferkamp S, et al. Aging Cell (2008) pmid: 18843795
231. Huot TJ, et al. Mol. Cell. Biol. (2002) pmid: 12417717
232. Rizos H, et al. J. Biol. Chem. (2001) pmid: 11518711
233. Gombart AF, et al. Leukemia (1997) pmid: 9324288
234. Yang R, et al. Cancer Res. (1995) pmid: 7780957
235. Parry D, et al. Mol. Cell. Biol. (1996) pmid: 8668202
236. Greenblatt MS, et al. Oncogene (2003) pmid: 12606942
237. Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) pmid: 10491434
238. Poi MJ, et al. Mol. Carcinog. (2001) pmid: 11255261
239. Byeon IJ, et al. Mol. Cell (1998) pmid: 9660926
240. Kannengiesser C, et al. Hum. Mutat. (2009) pmid: 19260062
241. Lal G, et al. Genes Chromosomes Cancer (2000) pmid: 10719365
242. Koh J, et al. Nature (1995) pmid: 7777061
243. McKenzie HA, et al. Hum. Mutat. (2010) pmid: 20340136
244. Miller PJ, et al. Hum. Mutat. (2011) pmid: 21462282
245. Kutscher CL, et al. Physiol. Behav. (1977) pmid: 905385
246. Scaini MC, et al. Hum. Mutat. (2014) pmid: 24659262
247. Jenkins NC, et al. J. Invest. Dermatol. (2013) pmid: 23190892
248. Walker GJ, et al. Int. J. Cancer (1999) pmid: 10389768
249. Rutter JL, et al. Oncogene (2003) pmid: 12853981
250. Itahana K, et al. Cancer Cell (2008) pmid: 18538737
251. Zhang Y, et al. Mol. Cell (1999) pmid: 10360174
252. Zhang Y, et al. Cell (1998) pmid: 9529249
253. Jafri M, et al. Cancer Discov (2015) pmid: 25873077
254. Whelan AJ, et al. N Engl J Med (1995) pmid: 7666917
255. Adv Exp Med Biol (2010) pmid: 20687502
256. Hogg D, et al. J Cutan Med Surg (1998) pmid: 9479083
257. De Unamuno B, et al. Melanoma Res (2018) pmid: 29543703
258. Soura E, et al. J Am Acad Dermatol (2016) pmid: 26892650
259. Huerta C, et al. Acta Derm Venereol (2018) pmid: 29405243
260. Kaufman DK, et al. Neurology (1993) pmid: 8414022
261. Bahuau M, et al. Cancer Res (1998) pmid: 9622062
262. Chan AK, et al. Clin Neuropathol () pmid: 28699883
263. Cui Y, et al. Clin. Cancer Res. (2012) pmid: 22753594
264. Haeger SM, et al. Oncogene (2016) pmid: 25893305
265. Bachet JB, et al. Ann. Oncol. (2012) pmid: 22377565
266. Witkiewicz AK, et al. Nat Commun (2015) pmid: 25855536
267. Jiao Y, et al. J. Pathol. (2014) pmid: 24293293
268. Churi CR, et al. PLoS ONE (2014) pmid: 25536104
269. Liu X, et al. Clin. Chem. (2014) pmid: 24821835
270. Maru D, et al. Oncogene (2004) pmid: 14647445
271. Wang K, et al. Oncologist (2015) pmid: 26336083
272. Nature (2014) pmid: 25079317
273. Izeradjene K, et al. Cancer Cell (2007) pmid: 17349581
274. Bardeesy N, et al. Genes Dev. (2006) pmid: 17114584
275. Springer S, et al. Gastroenterology (2015) pmid: 26253305
276. Blackford A, et al. Clin. Cancer Res. (2009) pmid: 19584151
277. Yan P, et al. Clin. Cancer Res. (2016) pmid: 26861460
278. Kozak MM, et al. J. Clin. Pathol. (2015) pmid: 25681512
279. Roth AD, et al. J. Natl. Cancer Inst. (2012) pmid: 23104212
280. Davison JM, et al. Am. J. Surg. Pathol. (2014) pmid: 24618609
281. Kim YH, et al. Ann. Oncol. (2004) pmid: 15033661
282. Xiangming C, et al. Clin. Cancer Res. (2001) pmid: 11234879
283. Singhi AD, et al. Am. J. Surg. Pathol. (2015) pmid: 25634752
284. Natsugoe S, et al. Clin. Cancer Res. (2002) pmid: 12060625
285. de Kruijf EM, et al. Ann. Oncol. (2013) pmid: 23022998
286. Shipitsin M, et al. Br. J. Cancer (2014) pmid: 25032733
287. Nat. Rev. Mol. Cell Biol. (2012) pmid: 22992590
288. Cell (2008) pmid: 18662538
289. Massagué J, et al. Genes Dev. (2005) pmid: 16322555
290. Morén A, et al. Oncogene (2000) pmid: 10980615
291. Xu J, et al. Proc. Natl. Acad. Sci. U.S.A. (2000) pmid: 10781087
292. Luo K, et al. Genes Dev. (1999) pmid: 10485843
293. Jones JB, et al. Nucleic Acids Res. (2000) pmid: 10871368
294. Fink SP, et al. Cancer Res. (2001) pmid: 11196171
295. De Bosscher K, et al. Biochem. J. (2004) pmid: 14715079
296. Shi Y, et al. Nature (1997) pmid: 9214508
297. Miyaki M, et al. Oncogene (1999) pmid: 10340381
298. Prokova V, et al. Biochemistry (2007) pmid: 17994767
299. Wu JW, et al. J. Biol. Chem. (2001) pmid: 11274206
300. Ding L, et al. J. Clin. Invest. (2009) pmid: 19139564
301. Kuang C, et al. Oncogene (2004) pmid: 14647410
302. Watanabe M, et al. EMBO Rep. (2000) pmid: 11265759
303. Houlston R, et al. Hum. Mol. Genet. (1998) pmid: 9811934
304. Woodford-Richens K, et al. Gut (2000) pmid: 10764709
305. Howe JR, et al. J. Med. Genet. (2004) pmid: 15235019

Electronically signed by Erik Williams, M.D. | 10 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

306. Brosens LA, et al. World J. Gastroenterol. (2011) pmid: 22171123
307. Kalia SS, et al. Genet. Med. (2017) pmid: 27854360
308. Cerami E, et al. Cancer Discov (2012) pmid: 22588877
309. Gao J, et al. Sci Signal (2013) pmid: 23550210
310. Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878
311. Kopp JL, et al. Cancer Cell (2012) pmid: 23201164
312. Zhong WD, et al. BMC Cancer (2012) pmid: 22703285
313. Wang L, et al. Med. Oncol. (2012) pmid: 22714060
314. Clemons NJ, et al. Am. J. Physiol. Gastrointest. Liver Physiol. (2012) pmid: 23064761
315. Pritchett J, et al. Trends Mol Med (2011) pmid: 21237710
316. Cunningham D, et al. N. Engl. J. Med. (2004) pmid: 15269313
317. Jonker DJ, et al. N. Engl. J. Med. (2007) pmid: 18003960
318. Di Bartolomeo M, et al. Target Oncol (2014) pmid: 23821376
319. Moiseyenko VM, et al. Clin Drug Investig (2018) pmid: 29470838
320. Stein et al., 2020; ASCO GI Abstract 96
321. Price TJ, et al. Lancet Oncol. (2014) pmid: 24739896
322. Sakai D, et al. Eur J Cancer (2020) pmid: 32526634
323. Van Cutsem E, et al. J. Clin. Oncol. (2007) pmid: 17470858
324. Peeters M, et al. Clin. Cancer Res. (2013) pmid: 23325582
325. Pietrantonio F, et al. JAMA Oncol (2019) pmid: 31268481

Electronically signed by Erik Williams, M.D. | 10 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531